Update on Avdoralimab Phase 2 Force Trial in COVID-19 Patients With Severe Pneumonia

NEXT STORY
Advaxis and Biosight Announce Entry into Definitive Merger Agreement
PREV STORY
HUTCHMED Initiates Phase I Trials of novel ERK inhibitor HMPL 295 in Patients with Advanced Solid Tumors in China
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Cybrexa Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of CBX-12 (alphalex™-exatecan) in Advanced or Metastatic Refractory Solid Tumors

author_avatar
NASDAQ Market News

eFFECTOR Presents Data on the Discovery and Structure of eFT226, a Novel Inhibitor of eIF4A, at the AACR 2018 Annual Meeting

author_avatar
NASDAQ Market News

Selecta Biosciences Announces Date of Second Quarter 2018 Financial Results Conference Call

WATERTOWN, Mass., Aug. 01, 2018 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB), a ...

author_avatar
NASDAQ Market News